Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- BURNS J. J., ROSE R. K., CHENKIN T., GOLDMAN A., SCHULERT A., BRODIE B. B. The physiological disposition of phenylbutazone (butazolidin) in man and a method for its estimation in biological material. J Pharmacol Exp Ther. 1953 Nov;109(3):346–357. [PubMed] [Google Scholar]
- GRAHAM W. The status of phenylbutazone (butazolidin) in the treatment of rheumatic disorders. Can Med Assoc J. 1958 Oct 15;79(8):634–638. [PMC free article] [PubMed] [Google Scholar]
- KERSLEY G. D., COOK E. R., TOVEY D. C. Value of uricosuric agents and in particular of G. 28 315 in gout. Ann Rheum Dis. 1958 Sep;17(3):326–333. doi: 10.1136/ard.17.3.326. [DOI] [PMC free article] [PubMed] [Google Scholar]
- MASON R. M., HAYTER R. R. The present status of phenylbutazone therapy in rheumatic disease. Practitioner. 1958 Jul;181(1081):23–28. [PubMed] [Google Scholar]
- OGRYZLO M. A., HARRISON J. Evaluation of uricosuric agents in chronic gout. Ann Rheum Dis. 1957 Dec;16(4):425–437. doi: 10.1136/ard.16.4.425. [DOI] [PMC free article] [PubMed] [Google Scholar]
- RICKARD CHRISTOPHERS, 80. Br Med J. 1953 Nov 28;2(4847):1214–1215. [PMC free article] [PubMed] [Google Scholar]
- YU T. F., BURNS J. J., PATON B. C., GUTMAN A. B., BRODIE B. B. Phenylbutazone metabolites: antirheumatic, sodium-retaining and uricosuric effects in man. J Pharmacol Exp Ther. 1958 May;123(1):63–69. [PubMed] [Google Scholar]